Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
24/2 16:00
Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022 Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers Symposium Genmab A/S (Nasdaq: GMAB) and Seagen Inc....